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Summary The aim of this study was to find predictors of neuropathy and reactions,
determine the most sensitive methods for detecting peripheral neuropathy, study the
pathogenesis of neuropathy and reactions and create a bank of specimen, backed up
by detailed clinical documentation. A multi-centre cohort study of 303 multibacillary
leprosy patients in Northern India was followed for 2 years. All newly registered MB
patients requiring a full course of MDT, who were smear positive and/or had six or
more skin lesions and/or had two or more nerve trunks involved, were eligible.
A detailed history was taken and physical and neurological examinations were
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performed. Nerve function was assessed at each visit with nerve conduction testing,
warm and cold detection thresholds, vibrometry, dynamometry, monofilaments and
voluntary muscle testing. Because the latter two are widely used in leprosy clinics,
they were used as ‘gold standard’ for sensory and motor impairment. Other outcome
events were type 1 and 2 reactions and neuritis. All subjects had a skin biopsy at
registration, repeated at the time of an outcome event, along with a nerve biopsy.
These were examined using a variety of immunohistological techniques. Blood
sampling for serological testing was done at every 4-weekly clinic visit. At diagnosis,
115 patients had an outcome event of recent onset. Many people had skin lesions
overlying a major nerve trunk, which were shown to be significantly associated with
an increased of sensory or motor impairment. The most important adjusted odds
ratios for motor impairment were, facial 4.5 (1·3–16) and ulnar 3·5 (1·0–8·5); for
sensory impairment they were, ulnar 2·9 (1·3–6·5), median 3·6 (1·1–12) and posterior
tibial 4·0 (1·8–8·7). Nerve enlargement was found in 94% of patients, while only 24%
and 3% had paraesthesia and nerve tenderness on palpation, respectively. These
increased the risk of reactions only marginally. Seven subjects had abnormal tendon
reflexes and seven abnormal joint position sense. In all but one case, these
impairments were accompanied by abnormalities in two or more other nerve function
tests and thus seemed to indicate more severe neuropathy. At diagnosis, 38% of a
cohort of newly diagnosed MB leprosy patients had recent or new reactions or nerve
damage at the time of intake into the study. The main risk factor for neuropathy found
in this baseline analysis was the presence of skin lesions overlying nerve trunks. They
increased the risk of sensory or motor impairment in the concerned nerve by 3–4
times. For some nerves, reactional signs in the lesions further increased this risk to
6–8 times the risk of those without such lesions. Patients with skin lesions overlying
peripheral nerve trunks should be carefully monitored for development of sensory or
motor impairment.
Introduction
Leprosy is feared because of the deformities and disability that it may cause.1 Successful
leprosy treatment should prevent or heal deformities and disabilities.2 Most of these are
secondary complications of impaired of nerve function, often caused by immunological
reactions against M. leprae antigens.3 Unfortunately, people remain at risk of neuropathy
resulting from such reactions during and even after successful anti-leprosy treatment.4 – 10
In the past decade, several large cohort studies conducted in Ethiopia, Nepal, Bangladesh
and Thailand have provided epidemiological data on prevalence and incidence of type 1
(reversal) and type 2 (ENL) reactions and sensory and motor impairment.5 – 12 These have
revealed a number of factors that increase the risk of immune reactions and nerve function
impairment (NFI). The main ones are extent of clinical disease,6 multibacillary (MB)
classification,13 and neuropathy already present at the time of diagnosis.10,13 However, these
three criteria apply to a fairly large proportion of cases detected in many programmes.
Worldwide in 2003, 39% of new cases were MB.14 The proportion of patients with nerve
function impairment (NFI) at diagnosis varies from 15% in Bangladesh15 to 55% in
Ethiopia.10 Prospective testing of immunological and neurological markers may reveal
additional factors that would enable more precise prediction of risk and thus more effective
preventive measures.
Despite advances in the understanding of some of the mechanisms underlying immune
reactions and neuropathy in leprosy, many questions related to the pathophysiology remain
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unanswered. Much of the current knowledge of leprosy reactions has been gained from cross
sectional studies, and there is little information on the longitudinal changes in immunological
and histopathological parameters over time. Improved understanding of the precise
mechanisms that trigger and modulate reactions may point to better methods of prevention
and treatment. Early detection of NFI is likely to be the most effective method of
prevention,7,13,16 indicating the importance of further studies to find out how early detection
of neuropathy is best achieved.
It was therefore proposed to study all three of the above areas, prediction, detection and
pathogenesis of reactions and NFI, in a large prospective study. The ILEP Nerve Function
Impairment and Reaction or ‘INFIR’ Cohort Study described in this paper was set up for this
purpose. The study is a multi-centre project involving two specialized leprosy referral
hospitals and two immunology laboratories in India, designed to address the following three
aims:
1. To find clinically relevant neurological and immunological predictors of NFI and
reactions.
2. To determine which method or combination of methods of nerve function assessment will
be most sensitive for the detection of sensory and motor impairment in leprosy.
3. To study the pathogenesis of peripheral neuropathy and reactions in leprosy with respect
to time of development of immunological, pathological, neurophysiological, and clinical
features.
This paper describes the main methods used in the study and the clinical profile of the intake
cohort. The neurological, immunological and histological profiles of the cohort will be the
subject of separate publications.
Materials and methods
DESIGN
This was a cohort study of newly registered MB patients. The patients were followed up
monthly for 1 year and every 2nd month during the 2nd year.
LOCATION
Recruitment of subjects took place in The Leprosy Mission (TLM) hospitals in Naini and
Faizabad, specialist leprosy referral centres in Uttar Pradesh, North India. The immunological
and histopathogical investigations were carried out at the LEPRA Blue Peter Research Centre
(BPRC) in Hyderabad, Andhra Pradesh and at the TLM Stanley Browne Laboratories in
Miraj, Maharashthra.
STUDY POPULATION
The study population comprised newly registered multibacillary leprosy patients requiring a
full course of MDT.
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STUDY SUBJECTS
Inclusion criteria
All newly diagnosed patients who were being registered for MDT and who were smear
positive and/or had six or more skin lesions and/or had involvement of two or more nerve
trunks were eligible for inclusion.
Exclusion criteria
The following categories of patients were excluded from the study, even if they met the
inclusion criteria:
. Patients who did not give consent to be enrolled in the study.
. Any patients for whom MDT was contraindicated.
. Relapses, restarters, defaulters and any other re-treatment patients, unless last MDT dose
was more than 5 years ago.
. Patients already on MDT, those transferred in from elsewhere and those transferred from
PB to MB MDT, unless they were within 1 month from diagnosis and had taken only one
dose of MDT.
. Patients under 12 or over 60 years of age.
. Patients already on steroid therapy for any reason.
. Patients with a history of alcohol abuse or diabetes.
. Patients with a history of or clinical signs of non-leprosy related peripheral neuropathies or
poliomyelitis.
. Patients mentally unable to cooperate with sensory and motor testing procedures (cannot
test).
. Patients living outside a predefined area around the study centre (within half a day travel).
. Patients who could not be expected to remain registered at the study centre for the time
span of the study (e.g. people working in seasonal labour and other temporary residents).
. Patients with a serious additional infection or condition, such as tuberculosis.
SUBJECT SELECTION
Not all potentially eligible patients were asked to enter the study. Whenever several eligible
new patients presented on a single day, those considered to be at highest risk of developing an
outcome event were selected first. This meant that those with more extensive disease and
positive skin smears were more likely to be selected than those with limited disease or a
negative skin smear. Patients without an outcome event at registration were given preference
over those with an event. Overall, however, it was only rarely necessary to choose between
eligible patients. Those selected were invited to participate. They were informed about the
procedure and could decline participation if they desired.
SAMPLING AND STUDY SIZE
The sample size calculations were based on odds ratio considerations for the ‘predictor part’
of the study. For a predictor present in 20% of the population, with an NFI frequency of 5% in
the unexposed group, a study size of 240 would have been needed to detect a relative risk of 4.
INFIR Cohort Study 17
To detect a difference of 20% between two predictive values (e.g. 60–40%), a sample size of
200 would have been sufficient. A study size of 300 was planned, including a contingency of
10–20% for loss to follow-up.
Patients who had a reaction or sensory or motor impairment at diagnosis were not
excluded from the study. They were given steroid treatment, or other anti-inflammatory
treatment as appropriate.
OUTCOME EVENTS
The following were counted as outcome events, neuritis, silent neuropathy (SN), type 1 or
reversal reaction (T1R), erythema nodosum leprosum (ENL or T2R), sensory impairment
(SI), motor impairment (MI). The latter two were only counted as outcome events if they
were of ‘recent’ onset, defined as 6 months or less. For the present analysis, only events
present at diagnosis were counted. The definitions are given in Appendix 1.
OUTCOME MEASURES
Predicting reactions and sensory and motor impairment
. The percentage of patients testing positive for a given measure or marker.
. The odds ratio of a given measure adjusted for other the effect of other measures that have
a significant influence on the model.
Early detection of sensory or motor impairment
. The positive predictive value (PPV), sensitivity and specificity of each test compared with
clinically significant NFI diagnosed with monofilaments (MF) or voluntary muscle test
(VMT).
GENERAL EXAMINATION AT INTAKE
A standardized history using a checklist was taken from all patients admitted to the study.
Patients were asked when they had first noticed signs or symptoms of the disease. They were
given a full physical examination and a basic neurological examination (including reflexes,
joint position sense and nerve palpation). Patients were assigned a leprosy classification
according to the Ridley–Jopling system, but based on clinical criteria (appearance, extent and
number of lesions, sensory impairment in the lesions and symmetry). The diagnosis of ‘pure
neural’ leprosy was based on finding one or more definitely enlarged nerve trunks. To be
eligible for the study, patients with pure neural leprosy had to have two or more enlarged
nerves. The location and appearance of skin lesions were recorded, and whether they were
overlying the course of a peripheral nerve trunk. Particular attention was given to signs and
symptoms of T1R, T2R and peripheral neuropathy. Slit skin smears were made from both
earlobes and from the edge of two active skin lesions. For serological investigations, 10 ml
blood was taken. Basic blood (haemoglobin levels, ESR and blood cell counts) and urine
analysis were performed at the local laboratory.
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TREATMENT REGIMEN
All patients were put on WHO multidrug therapy for multibacillary patients (MB MDT),
consisting of daily dapsone (100 mg) and clofazimine (50 mg) and monthly supervised
rifampicine (600 mg) and clofazimine (300 mg). Patients whose average bacteriological
index (BI) at diagnosis was ,3 received 12 months of MB MDT; others were treated for
24 months.
NERVE FUNCTION ASSESSMENT
In view of the purpose of the study, namely to investigate in detail prediction, detection and
pathogenesis of immunological reactions and neural impairment in leprosy, a number of tests
of nerve function not routinely used in leprosy were incorporated in the protocol, along with
standard tests. Motor and sensory impairment as outcome events were defined on the basis of
an abnormal VMT or monofilament (MF) test result, because these are standard tests that are
widely used. Nerve function assessment was done using the following methods.
History taking
A set of standardized questions was used that might detect current NFI or give warning signs
for future outcome events. The questions are given in Appendix 2.
Motor nerve function
Voluntary muscle testing (VMT) using the 0–5 modified MRC scale (see Appendix 3).
Grip dynamometry, key pinch and pulp-to-pulp pinch testing. The dynamometer was
made of a sphygmomanometer cuff inserted in a cylindrical cotton cover and inflated to a
baseline pressure of 20 mmHg. Pulp-to-pulp and key-pinch strength was measured in a
similar way using a neonatal sphygmomanometer cuff.17
Motor nerve conduction measurements (MNC). MNC parameters were measured on three
nerves bilaterally (ulnar, median and lateral popliteal (peroneal)) using Neurocare 2000 EMG
machines (BioTech Ltd., Mumbai). The Windows-driven software stores the compound
muscle action potential traces in a database for future reference. The measured values for
latency, amplitude and distance were stored automatically in a separate Access database. The
Neurocare software calculated nerve conduction velocity (NCV) and area under the curve
values. Skin temperatures were measured bilaterally at wrist and ankle with an electronic
thermometer (Testo Quicktemp 925, with a surface probe no. 0602.0392). The NCV and
distal latency values were corrected for temperature at the time of analysis using standard
formulae.
Sensory nerve function
Touch sensation was tested using a standard set of coloured Semmes–Weinstein
monofilaments (MF.18 The monofilaments used were 200 mg, 2 g, 4 g, 10 g and 300 g.
Normal reference values were 200 mg for the hand and 2 g for the foot (excluding the heel).19
The test sites and scoring methods are given in Appendix 5.
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Vibration perception thresholds (VPT). Vibration sensation was tested with a Vibrameter
II (Somedic, Sweden). The instrument provides application force-controlled measurements of
the VPTs in microns of skin displacement, using an algorithm of limits (slowly increasing
vibration amplitude, until the person tested indicates that (s)he can feel the vibration. The test
sites were the thenar and hypothenar eminences (soft tissue), for testing the median and ulnar
nerve, respectively, the dorsal first webspace for the radial cutaneous nerve, the plantar pulp
of the big toe (posterior tibial) and the mid-lateral border of the foot (sural). All tests were
done bilaterally.
Thermal detection thresholds. Thermal thresholds were evaluated using an instrument
called the Thermal Sensory Analyzer (TSA II), manufactured by MEDOC in Israel. The TSA
is capable of measuring warm detection thresholds (WDT) and cold detection thresholds
(CDT), as well as heat pain (HP) and cold pain (CP). In this study, only the former two were
recorded. The WDT and CDT were measured relative to a baseline thermode temperature of
328C. The algorithm used for determining the threshold was the ‘method of levels’.20 The test
sites were the same as for vibrometry, described above.
Sensory nerve conduction measurements (SNC). SNC parameters were measured
bilaterally on four nerves (radial cutaneous, ulnar, median and sural) using the same
equipment as described for MNC.
The neurological methods and results will be presented and discussed in subsequent
papers. The thresholds for impairment were based on the normative studies done as part of
this project and which are reported in separate publications (Nicholls et al., in preparation;
van Brakel et al., in preparation). The diagnoses of sensory impairment and motor
impairment were based on the results of the MF and the VMT, respectively.
ACTIVITIES OF DAILY LIVING (ADL)
A questionnaire-based ADL assessment was done, using the Green Pastures Activity Scale,21
to evaluate neurological disability at the time of diagnosis and when an outcome event was
diagnosed.
BIOPSIES
A full-thickness biopsy was taken from the edge of an active skin lesion. In those
experiencing an outcome event, a further skin biopsy was obtained from the same lesion. The
biopsies were fixed according to standard protocols. Half of each biopsy was fixed in
formalin; the other half was snap-frozen in liquid nitrogen. In patients with recent sensory or
motor impairment (onset #6 months), a nerve biopsy was taken from a cutaneous nerve on
one affected limb. For the upper limb, the radial cutaneous nerve was used; for the lower
limb, the sural nerve. Nerve biopsies were also fixed in liquid nitrogen. Biopsies were divided
transversely and fixed in the same way as the skin biopsies. Reading of biopsies was done
blinded to the clinical outcome diagnosis.
IMMUNOLOGICAL EVALUATION
Blood samples were taken during follow-up visits and at the time an outcome event was
diagnosed. Samples were prepared according to standard procedures, detailed in the INFIR
Field Procedures Manual. Serum was separated, aliquoted and stored in liquid nitrogen. As a
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precaution, four blood drops from each sample were put on Whatman filter paper, dried and
stored. Once a month, these were sent to the designated laboratories in liquid nitrogen
transport containers. The immunological investigations were performed at the designated
laboratories. Samples not needed for the immediate serological investigations are stored
frozen at2708C in a specimen bank. Once during the follow-up a separate blood sample was
taken for future DNA analysis.
CLASSIFICATION AND CERTAINTY OF OUTCOME DIAGNOSIS
Initially, classification according to the Ridley–Jopling system and diagnosis of outcome
events were based on clinical criteria initially. Treatment of reactions or nerve function
impairment was therefore based on the physician’s diagnosis. After data collection of the first
year of follow-up had finished, all outcome diagnoses were reviewed and checked for
consistency with the criteria set in the protocol. Each outcome event was assigned a certainty
grade 1–3 (1 ¼ doubtful; 3 ¼ definite). Subjects with a grade 2 or 3 outcome event were
counted as ‘cases’; the remainder of the cohort were used as the control group. A few ‘missed
events’ were also found and added as outcome in retrospect. Most frequently this had
happened when NFI had developed slowly over a period of several months, but still within the
stipulated maximum of 6 months. When the histological results became available, the
classification data and outcome events were reviewed again and clinical and histological data
were reconciled to give a final classification and outcome certainty level. With regard to the
Ridley–Jopling classification, the histological findings took precedence over clinical
classification, so a patient classified clinically as BT but with BL histology would have final
BL classification. For multivariate analysis, the classification groups were collapsed to either
T(uberculoid) or L(epromatous). ‘T’ includes skin smear negative BT and pure neuritic (PN)
leprosy with BT histology. ‘L’ includes skin smear positive BT, BL, LL and PN with BL
histology or .3 nerves enlarged.
For the final diagnosis of outcome events, the clinical diagnosis prevailed, but
discrepancies were noted and a sub-group analysis exploring these will be done at a later
stage. In cases with an outcome certainty level of ‘1’ (doubtful) in whom histology showed
signs of T1R or T2R, the certainty level was changed to ‘2’. Subjects in whom a reaction was
detected in the skin biopsy, but not clinically (n ¼ 44), were not counted among cases with
outcome events. Excluded from the control group were those with an event certainty status of
‘1’ and those who developed an incident reaction within 6 months of registration. Only events
with a certainty level of 2 or 3 were included as outcome events in the analysis.
FOLLOW-UP
The patients were followed up monthly for the first year and every second month during the
second year. Patients who did not report for their follow-up appointment were visited at home
within 1 week of the due date. During these home visits the reason for missing the
appointment was determined and the patient was counselled to return for treatment and
investigations. At each follow-up, the patients had a physical examination and a full nerve
function assessment as detailed above. A blood sample was also taken.
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ANALYSIS OF RESULTS
Prevalence estimates are given as percentages with 95% confidence intervals for the point
estimates. Delay in presentation was calculated as the interval between the time the patient
had first notice a sign or symptom of the disease and the date of diagnosis. The significance of
associations between outcome and predictor variables was tested using the Chi-squared or
Fisher’s exact test. Differences between means and differences between medians were tested
with the t-test and the Kruskal–Wallis test, respectively. Univariate and multivariate analyses
of associations between outcome and predictor variables were done with normal or stepwise
logistic regression. Analyses were performed using Stata for Windows software, versions
7 and 8.
ETHICAL CONSIDERATIONS
No financial incentives were given to participants. However, travel expenses were refunded
on occasion and, where relevant, lost earnings of daily labourers compensated. The study
adhered to the International Ethical Guidelines for Biomedical Research Involving Human
Subjects (CIOMS/WHO, 1993). Permission for the study was obtained from the Indian
Council of Medical Research and the Research Ethics Committee of the Central JALMA
Institute for Leprosy in Agra gave ethical approval. This included permission for the skin and
nerve biopsies. Written consent was obtained from individual study subjects before inclusion
in the study, using a standard consent form.
Results
Three hundred and three subjects were enrolled in the study, of whom 83 were women (27%).
The mean age was 32·8 years (range 12–60). Demographic and clinical details are presented
in Table 1. Over 50% had grade 1 or 2 impairment and 36% were smear-positive. Twenty-one
percent had an average BI of 3 or more.
The prevalence of reactions, sensory and motor impairment and neuritis is shown in
Table 2. Altogether, 115 subjects had a reaction or NFI event at registration. Sixty-four (21%)
had sensory or motor impairment of recent onset. Only six people (2.3%) had a T2R. Table 3
gives details of the reactional signs and symptoms. Involvement of other organs and nerve
pain and tenderness disturbing sleep or activities were rare.
Many subjects had skin lesions overlying a major nerve trunk (Table 4). Table 5 shows
the association between the presence of such a lesion, with and without a reaction, and neural
impairment in that nerve. In univariate analysis, lesions overlying the facial and ulnar nerve
had a statistically significant association with motor impairment, while lesions overlying the
ulnar, median and posterior tibial nerve were associated with sensory impairment. However,
when adjusting for the effects of age, sex, leprosy type, BI and old nerve damage, the
association between lesions overlying the ulnar nerve and motor impairment was no longer
significant at the 5% level. The odds ratios were generally higher for the presence of
reactional skin lesions than for any skin lesions. The latter were more consistent and had
smaller confidence intervals, probably because of the much larger number of people with
non-reactional lesions. Even in multivariate analyses, associations between skin lesions
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overlying nerves and impairment of the facial, ulnar, median (sensory only) and posterior
tibial nerves were statistically significant.
The prevalence of palpable nerve enlargement, tenderness, paraesthesia on palpation,
absent joint position sense or abnormal tendon reflexes in each nerve is shown in Tables 6
and 7, respectively. Nerve enlargement was very common in this cohort (.94% had one or
more enlarged nerves). In contrast, paraesthesia and tenderness on palpation were much less
common (24% and 3%, respectively). Very few subjects had abnormal reflexes or JPS,
despite sensory or motor impairment in the same limb. However, detailed analysis of those
Table 1. Characteristics of the subjects in the INFIR Cohort Study (n=303) at the time of registration
Variable Frequency Percentage
Sex
Men 220 72·6
Women 83 27·4
Age group
12–20 56 18·5
21–30 97 32·0
31–40 71 23·4
41–50 61 20·1
51–60 18 6·0
Classification
BT* 180 59·4
BL* 81 26·7
LL* 29 9·6
PN* 13 4·3
WHO disability grade
0 150 49·5
1 124 40·9
2 29 9·6
Delay in presentation
Up to 6 months 91 30·0
7–12 96 31·8
13–24 52 17·2
25–36 28 9·3
37–60 19 6·3
.60 months 16 5·4
Average BI**
0 193 63·7
Up to and including 1 20 6·6
Up to and including 2 27 8·9
Up to and including 3 21 6·9
Up to and including 4 24 7·9
Up to and including 5 16 5·3
Up to and including 6 2 0·66
Right eye Left eye
Visual acuity n % n %
6/6 216 71·3 212 70·0
6/9–6/12 54 17·8 62 20·5
6/18–6/60 28 9·2 28 9·2
,6/60 3 0·99 1 0·33
Missing 2 0·66
* BT ¼ borderline tuberculoid, BL ¼ borderline lepromatous, LL ¼ lepromatous and PN ¼ pure
neuritic (classification based on clinical and histological criteria).
** BI ¼ bacteriological index of the skin smear (rounded; up if,1, otherwise down to nearest integer).
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patients whose JPS or reflexes were abnormal showed two things. Firstly, the abnormalities
were mutually exclusive, i.e. those with abnormal reflexes had normal JPS and vice versa,
and, secondly, abnormal reflexes or JPS were in all but one case accompanied by
abnormalities in more than one other nerve function test (data not shown). Impaired JPS or
reflexes were not associated with the presence reactions or NFI at diagnosis (Table 8).
Table 8 shows the results of univariate and multivariate analysis of the association
between these neurological tests and the event status at registration. After adjusting for the
effects of age, sex and leprosy type, none of the signs was independently associated with an
increased risk of reaction or NFI. The presence of one or more tender nerves appeared to be
associated with an increased risk of reaction or NFI (odds ratio 7.3), but this was not
significant at the 5% level (P ¼ 0.084).
Discussion
The current cohort consisted of 188 patients without reaction or NFI at intake and 115 with
such an event. In the latter group, the progress of clinical, neurophysiological and
immunological markers during reaction treatment were studied, as well as risk factors for
reoccurrence of reaction or NFI during and after reaction treatment. In the former group, risk
factors for occurrence of reactions and NFI and methods for early detection of sensory and
Table 2. Reactions observed at the time of registration among the subjects in
the INFIR Cohort Study (n ¼ 303)
Variable Frequency Percentage
Type 1 reaction
All 60 19·8
Mild 23 7·6
Severe* 37 12·2
Type 2 reaction
All 6 2·0
Mild 4 1·3
Severe* 2 0·7
Nerve function impairment
Old 79 26·1
Recent** 64 21·1
Any 143 47·2
Sensory – old 96 31·7
Recent** 48 15·8
Any 127 41·9
Motor – old 26 8·6
Recent** 33 10·9
Any 59 19·5
Both sensory and motor (recent) 17 5·6
Other neuritis*** 29 9·6
* A reaction was called ‘severe’ if one or more of the following signs or
symptoms were present: sensory or motor impairment, ulcerating skin lesions,
.10 reactional skin lesions, oedema that impaired function, ‘visible’ nerve
tenderness on gentle palpation, despite distraction, paraesthesia or nerve pain
disturbing sleep or impairing function or involvement of other organs, like
eyes, joints, testis, etc.
** Onset 6 months ago or less.
*** See definition in Appendix 1.
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Table 3. Reactional signs and symptoms at the time of registration among the
subjects in the INFIR Cohort Study (n ¼ 303)
Variable Frequency Percentage
Raised skin lesions
None 239 78·9
1–3 9 3·0
4–10 22 7·3
.10 33 10·9
Degree of inflammation
None 240 79·2
Erythema or nodules 35 11·6
Erythema and raised plaques or
nodules
28 9·2
Ulceration 0
Reactional oedema
None 271 89·4
Minimal 19 6·3
Visible, but not affecting
function
13 4·3
Affecting function 0
Fever due to reaction
,37·58C 299 98·7
37·6–38·98C 4 1·3
$398C 0
Involvement of other organs*
None 301 99·3
Mild 1 0·33
Definite 1 0·33
Nerve pain and/or paraesthesia
None 277 91·4
Intermittent; not limiting activity 23 7·6
Sleep disturbed and/or activity
diminished
1 0·33
Incapacitating 2 0·66
Nerve tenderness
None 275 90·8
Absent if attention distracted 23 7·6
Present if attention distracted 2 0·70
Withdraws limb forcibly 3 0·99
* For example, eyes, joints or testis.
Table 4. Prevalence of skin lesions overlying a major nerve trunk among subjects with reactional skin lesions (n=62)
and in the whole cohort at the time of registration in the INFIR Cohort Study (n ¼ 303)
With reaction Any skin lesions
Right Left Right Left
Nerve n* % n* % n* % n* %
Facial 28 45·2 23 37·1 75 24·8 70 23·1
Ulnar 30 48·4 27 41·9 126 41·6 120 39·6
Median 9 14·5 12 19·4 32 10·6 36 11·9
Peroneal 18 29·0 16 25·8 76 25·1 72 23·8
Posterior tibial 13 21·0 13 21·8 30 9·9 35 11·6
* n=number of subjects with a lesion overlying the nerve on that side.
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Table 5. Association (odds ratios) between skin lesions overlying a nerve trunk and neural impairment in the same nerve in the INFIR Cohort Study (n=512 nerves*) at the time
of registration
Reactional skin lesions Any skin lesions
Nerve Motor impairment
Sensory
impairment
Sensory or motor
impairment
Motor
impairment
Sensory
impairment
Sensory or motor
impairment
Facial Univariate 7·1** (2·2–23) 4·6 (1·4–15)
Multivariate*** 6·8 (1·9–27) 4·5 (1·3–16)
Ulnar Univariate 3·1 (1·3–7·4) 1·4 (0·51–3·7) 1·7 (0·73–3·7) 3·3 (1·5–7·3) 2·3 (1·2–4·8) 2·6 (1·4–4·8)
Multivariate 2·4 (0·88–6·5) 1·6 (0·50–5·1) 1·7 (0·66–4·2) 3·5 (1·0–8·5) 2·9 (1·3–6·5) 2·8 (1·5–5·6)
Median Univariate 11 (0·97–127) 7·1 (2·2–24) 6·2 (1·9–20) 3·9 (0·34–44) 4·2 (1·5–12) 3·5 (1·3–9·6)
Multivariate 28 (0·64–1238) 8·3 (1·9–39) 7·7 (1·6–36) 3·4 (0·21–56) 3·6 (1·1–12) 3·2 (1·0–10)
Peroneal Univariate No recent outcome
events
Posterior
tibial
Univariate 2·6 (1·0–6·4) 3·0 (1·6–5·6)
Multivariate 4·3 (1·4–14) 4·0 (1·8–8·7)
* Subjects who developed an incident reaction within the first 6 months from registration were excluded as controls (n ¼ 47).
** OR ¼ odds ratio; 95% CI ¼ 95% confidence interval; the odds ratios blocked in grey are statistically significant at the 5% level.
*** Adjusted for age, sex, leprosy type, BI and longstanding neuropathy in the same nerve.
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motor impairment were investigated. These investigations will be reported elsewhere. A range
of sero-immunological and immunohistochemical markers were studied as potential markers
to predict reactions and NFI, as well as to increase our understanding of pathogenesis of such
events. These results will be reported elsewhere. The cohort was selected with a bias towards
patients expected to be at high risk of reactions and NFI. Therefore, no epidemiological
conclusions can be drawn from the prevalence or incidence of these events in the cohort.
SKIN LESIONS OVERLYING A MAJOR NERVE TRUNK
Hogeweg et al. showed that skin lesions on the face, accompanied by signs of type 1 reaction
(T1R), substantially increased the risk of motor impairment of the facial nerve.22 Many
believe this to be true also for reactional skin lesions overlying other major nerve trunks, but
Table 6. Prevalence of palpable nerve enlargement, tenderness and paraesthesia in the INFIR Cohort Study (n ¼ 303)
at the time of registration
Ulnar Median Radial Peroneal Post Tibial Sural
Right Left Right Left Right Left Right Left Right Left Right Left
Enlarged
No 67 62 208 220 124 126 110 94 87 82 121 118
Possible 51 55 51 50 48 62 62 65 61 62 61 62
Definite 185 186 44 33 131 115 131 144 141 140 107 102
% definite 61·1 61·4 14·5 10·9 43·2 38·0 43·2 47·5 46·5 46·2 35·3 33·7
Missing 14 19 14 21
Tender
No 284 288 293 294 296 295 293 290 268 261 280 271
Mild 16 11 9 8 5 6 9 11 22 23 12 12
Moderate 3 4 1 1 2 2 1 2 2 4 3
% moderate 0·99 1·3 0·33 0·33 0·66 0·66 0·33 0·66 0·66 1·3 0·99
Severe
Missing 11 15 11 17
Paraesthesia
No 274 272 287 288 294 288 275 276 266 258 276 271
Yes 29 31 16 15 9 15 28 27 26 30 16 15
% yes 9·6 10·2 5·3 5·0 3·0 5·0 9·2 8·9 8·6 9·9 5·3 5·0
Missing 11 15 11 17
Table 7. Prevalence of abnormal neurological test results in the INFIR Cohort Study (n ¼ 303) at the time of registration
Index finger Little finger Big toe
Test Right Left Right Left Right Left Right Left Right Left
Joint position sense
Absent 1 0 3 2 0 1
% absent 0·33 0·99 0·66 0·33
Biceps Triceps Supinator Knee jerk Ankle
Reflexes*
Missing data 1 2
Normal 301 302 299 301 296 297 292 292 301 296
Brisk 2 1 1 1 2 1 11 9 1 1
Absent 3 1 5 5 1 1 4
% absent 0 0 0·99 0·33 1·65 1·65 0 0·33 0·33 1·32
* Only seven subjects had an absent tendon reflex on only one side.
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evidence for this has been lacking. The current study specifically noted the presence and
location of skin lesions and thus provided the basis for a detailed risk analysis. Even after
adjusting for the effects of major other risk factors such as age, sex, leprosy type and pre-
existing nerve damage, the presence of skin lesions overlying most nerve trunks included in
the study increased the risk of accompanying NFI by 3–4 times (Table 5). One caution is that
the present cross-sectional analysis could not prove that the lesions actually preceded the
reaction or NFI. The presence of a reaction increased the strength of the association for most
nerves, although confidence intervals were much wider due to the much smaller number of
subjects with reactional skin lesions. These findings indicate that the presence of skin lesions
overlying a nerve trunk perhaps is more important than whether or not this lesion is in
reaction. Patients with skin lesions overlying peripheral nerve trunks should be carefully
monitored for development of sensory or motor impairment.
JOINT POSITION SENSE AND TENDON REFLEXES
These tests, though part of a routine neurological examination,23 are often omitted in the
examination of patients with leprosy, because proprioception and deep reflex pathways are
not expected to be affected. However, Jennekens and Jennekens found abnormal position
sense of one or more digits in 33% of the patients they examined.24 van Brakel et al. found
abnormal position sense in 2% of median and 10% of ulnar and posterior tibial nerves.25
Ramadan et al. found ‘diminished’ reflexes in 18/40 of their patients and ‘diminished joint
and vibration sensation’ in 13/40. However, the patient group in the latter study was older and
had longer histories of leprosy than the present study group. In our study, although only,2%
of subjects had abnormal JPS or reflexes, this was accompanied by multiple other abnormal
test results, perhaps indicating more advanced neuropathy. This confirms our earlier findings
regarding JPS25 and fits with the assessment that abnormal JPS indicates ‘a severe
impairment of the distal, thick sensory fibres’.24 Prospective analysis from the INFIR Cohort
Study will show whether these tests also have value for predicting neuropathy and prognostic
value with regard to treatment outcomes.
Table 8. Association between clinical and neurological parameters and outcome status at registration in the INFIR
Cohort Study (n=256*)
Sign
Reaction
(n=115)
No reaction
(n=141) Univariate analysis Multivariate analysis**
.4 nerves enlarged 64 54 2·0 (1·2–3·3) 1·7 (0·99–3·0)
Up to 4 nerves enlarged 51 87
1 or more nerves tender 6 1 7·7 (0·91–65) 7·0 (0·75–66)
No tender nerves 109 140
.1 nerve paraesthesia*** 30 22 1·9 (1·0–3·5) 1·6 (0·83–3·2)
No or 1 nerve with paraesthesia 85 119
Absent JPS 2 2 1·3 (0·17–9·0) 2·6 (0·31–21)
Normal JPS 111 139
Abnormal reflexes 3 3 1·2 (0·24–6·2) 1·6 (0·28–8·5)
Normal reflexes 112 138
* Subjects who developed an incident reaction within the first 6 months from registration were excluded as controls
(n ¼ 47).
** Adjusted for each of the variables in the table plus age, sex and leprosy type.
*** On palpation.
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NERVE ENLARGEMENT, TENDERNESS AND PARAESTHESIA
Nerve enlargement, tenderness and paraesthesia on palpation were associated with an
increased risk of a reaction or a NFI event at diagnosis. However, after controlling for the
effects of other variables, these associations failed to reach statistical significance. The reason
in the case of tenderness may be that it occurred in only 0.7% of subjects (5% among those
with an outcome event). This may be partly due to the fairly conservative criterion used for
the diagnosis ‘tenderness’. Only ‘moderate’ or ‘severe’ tenderness was counted in the
analysis (see Appendix 1).
Conclusion
The main finding in this cross-sectional analysis is that skin lesions overlying major nerve
trunks increase the risk of nerve damage in these nerves significantly, irrespective of whether
these lesions show signs of a skin reaction. Absent joint position sense or tendon reflexes
appear to indicate more advance neuropathy. Nerve enlargement, tenderness and paraesthesia
on palpation were associated with an increased risk of a reaction or a NFI event at diagnosis,
but this association was not very strong. The nerve function of patients with these signs and
symptoms should be monitored regularly.
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Appendix 1: Outcome definitions and diagnostic cut-offs
Neuritis
A leprosy patient had neuritis if he/she had any of the following:
. Spontaneous nerve pain, paraesthesia or tenderness.
. New sensory or motor impairment of recent onset.
. Mixed signs neuritis.
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A neuritis may be mild or severe (see below), acute (,1 month duration), sub-acute (2–6
months) or long-standing (.6 months). During the monthly study follow-ups, only acute
neuritis was regarded as an as outcome.
Silent neuropathy (SN)
A patient had silent neuropathy when he/she had sensory and/or motor impairment of recent
onset (,6 months duration) in an area innervated by one or more nerve without signs of a
reaction (RR or ENL) or nerve pain and with or without tenderness.
Type 1 or reversal reaction (T1R)
A type 1 reaction was diagnosed when a patient had erythema and oedema of skin lesions.
There may be accompanying neuritis and oedema of the hands, feet and face. The skin signs
are obligatory; the nerve and general signs optional.
Erythema nodosum leprosum (ENL)
A patient had ENL if he/she had crops of tender subcutaneous skin lesions. There may be
accompanying neuritis, iritis, arthritis, orchitis, dactylitis, lymphadenopathy, oedema and
fever. The skin signs are obligatory; the nerve and general signs optional.
Severity of a reaction
A reaction was called ‘severe’ if one or more of the following signs or symptoms were
present: sensory or motor impairment, ulcerating skin lesions, .10 reactional skin lesions,
oedema that impaired function, ‘visible’ nerve tenderness on gentle palpation, despite
distraction, paraesthesia or nerve pain disturbing sleep or impairing function or involvement
of other organs, such as eyes, joints, testis, etc.
Sensory impairment (SI)
A patient was diagnosed as having sensory impairment in any of the following situations: the
monofilament threshold was increased from the normal threshold (200 mg for the hand and
2 g for the foot) by three or more levels (filaments) on any site, OR two levels on one site
AND at least one level on another site, OR one level on three or more sites for one nerve.
Only SI of recent onset (6 months or less) was counted as an outcome event.
Motor impairment (MI)
A patient was diagnosed as having motor impairment if the VMT score for any muscle was
less than four on the 0–5 (modified) MRC scale. Only MI of recent onset (6 months or less)
was counted as an outcome event.
New additional sensory or motor impairment
Where the baseline showed partial or full longstanding impairment for two or more
consecutive assessments, then if the DIFFERENCE in ‘levels’ (between now and the
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baseline) was 3 or more for monofilaments or 2 or more for VMT, then the patient had
additional recent impairment and should be considered as having an outcome event.
Nerve enlargement
Scoring=none, possible or definite. Only nerves scoring ‘definite’ were included as ‘enlarged’
in the analysis.
Nerve tenderness
Scoring:
. Absent
. Mild – absent if patient’s attention is distracted
. Moderate – present if patient’s attention is distracted
. Severe – patient withdraws the arm forcibly
Only nerves scoring ‘moderate’ or ‘severe’ were counted for the analysis.
Paraesthesia
Nerves were marked positive for paraesthesia if the patient reported sensations of tingling,
pricking or something equivalent while the nerve was gently palpated.
Joint position sense
Scoring:
0 or 1 correct responses in 3 trials
2 or 3 correct responses in 3 trials
Tendon reflexes
Scoring: absent, normal or brisk/exaggerated. Only single-sided absence of reflexes was
counted as abnormal.
Appendix 2
Standard questions asked as part of the history taking:
. Did you notice any new loss of sensation in your hands or feet during the past month?
. Did you notice any new dryness of your hand palms or foot soles during the past month?
. Did you notice any new weakness in your hands or feet during the past month?
. Did you notice any new sensations of pin and needles or ‘insects crawling’ in your hands or
feet during the past month?
. Did you notice any new pain sensations, such as burning or shooting pain in your hands or
feet during the past month?
If a question was answered positively, the person was asked which limb was affected. This
was recorded on the form. Paraesthesia and pain were graded on a 4-point scale:
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. Absent
. Mild – only aware intermittently; does not limit activity
. Moderate – sleep disturbed and/or activities (including work) diminished
. Severe – incapacitating
Appendix 3: voluntary muscle testing
Movements tested per nerve
Tight eye closure – facial nerve (orbicularis oculi)
Thumb abduction – median nerve (abductor pollicis brevis)
Little finger abduction – ulnar nerve (abductor digiti minimi)
Wrist extension – radial nerve (extensor muscles)
Foot dorsiflexion – lateral popliteal nerve (tibialis anterior and peroneus longus and
brevis)
If any particular muscle could not be tested (e.g. because of joint stiffness or previous
surgery), a missing value (9) was recorded for the nerve score. Similarly, if test data are not
available for any particular follow-up time, a missing value was recorded.
Grading criteria for the voluntary muscle test
Appendix 4: Semmes–Weinstein monofilaments
Recording
Coloured pens of appropriate colours (blue, purple (or black), red, orange, pink).
Test sites
On the ulnar side of the hand:
Hypothenar eminence
Fifth metacarpal head (MCP 5)
Volar surface of the distal phalanx of the little finger
On the median side of the hand:
Thenar eminence
Volar surface of the distal phalanx of the thumb
Grade Criteria
5 Full range of movement of the joint on which the muscle or muscle group is acting; normal
resistance can be given (forced eye closure)
4 Full range of movement but less than normal resistance
3 Full range of movement but no resistance
2 Partial range of movement with no resistance (lidgap on tight eye closure)
1 Perceptible contraction of muscle(s) not resulting in joint (or eyelid) movement
0 Complete paralysis
Criteria for motor impairment was any muscle scoring ,4.
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Volar surface of the distal phalanx of the index finger
For the radial cutaneous nerve:
Dorsal on the thumb, at the site of the motor point
On the foot:
Plantar surface of the distal phalanx of the big toe
First metatarsal head
Fifth metatarsal head
Plantar surface near lateral border of the foot
Lateral border of the foot (just distal from the head of the fifth metatarsal bone)
Scoring
The score for individual sites is summed for each nerve:
Ulnar: 3 sites
Median: 3 sites
Radial cutaneous: 1 site
Posterior tibial: 4 sites
Sural: 1 site
Criterion for sensory impairment
If a patient scores 3 or more for any nerve, the nerve had sensory impairment. The normal
sensation level for all sites on the hand is 200 mg; The normal sensation level for all sites on
the foot is 2 g.
Hand Foot
Colour Approximate force Score Colour Approximate force Score
Blue filament felt 200 mg 0 Purple filament felt 2 g 0
Purple filament felt 2 g 1 Red filament felt 4 g 1
Red filament felt 4 g 2 Orange filament felt 10 g 2
Orange filament felt 10 g 3 Pink filament felt 300 g 3
Pink filament felt 300 g 4 Pink not filament felt 4
Pink filament not felt 5
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